XML 31 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Earnings per Share (Tables)
6 Months Ended
Jul. 29, 2017
Earnings Per Share [Abstract]  
Computation of basic and diluted earnings per share
The following tables show the computation of basic and diluted (loss) earnings per common share for each period presented (in thousands, except per share amounts):
 
Three Months Ended
 
Six Months Ended
 
July 29, 2017
 
July 30, 2016
 
July 29, 2017
 
July 30, 2016
Basic:
 
 
 
 
 
 
 
Net (loss) income
$
(6,258
)
 
$
41

 
$
(25,245
)
 
$
(15,419
)
Less: Allocation of earnings to participating securities
(51
)
 

 
(202
)
 

Net (loss) income allocated to common shares
(6,309
)
 
41

 
(25,447
)

(15,419
)
 
 
 
 
 
 
 
 
Basic weighted average shares outstanding
27,535

 
27,111

 
27,401

 
27,021

Basic (loss) earnings per share
$
(0.23
)
 
$

 
$
(0.93
)
 
$
(0.57
)
 
 
 
 
 
 
 
 
 
Three Months Ended
 
Six Months Ended
 
July 29, 2017
 
July 30, 2016
 
July 29, 2017
 
July 30, 2016
Diluted:
 

 
 

 
 
 
 
Net (loss) income
$
(6,258
)
 
$
41

 
$
(25,245
)
 
$
(15,419
)
Less: Allocation of earnings to participating securities
(51
)
 

 
(202
)
 

Net (loss) income allocated to common shares
(6,309
)
 
41

 
(25,447
)

(15,419
)
 
 
 
 
 
 
 
 
Basic weighted average shares outstanding
27,535

 
27,111

 
27,401

 
27,021

Add: Dilutive effect of stock awards

 
64

 

 

Diluted weighted average shares outstanding
27,535

 
27,175

 
27,401


27,021

Diluted (loss) earnings per share
$
(0.23
)
 
$

 
$
(0.93
)
 
$
(0.57
)
Number of anti-dilutive securities excluded from computation of diluted loss per share
The number of shares attributable to SARs and non-vested stock grants that would have been considered dilutive securities, but were excluded from the calculation of diluted loss per common share because the effect was anti-dilutive were as follows (in thousands):
 
Three Months Ended
 
Six Months Ended
 
July 29, 2017
 
July 30, 2016
 
July 29, 2017
 
July 30, 2016
Number of anti-dilutive shares due to net loss for the period

 

 

 
53

Number of anti-dilutive SARs due to exercise price greater than average market price of our common stock
119


194

 
138

 
203